

## Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

June 9, 2017

## Live Audio Webcast Will be on June 15, 2017

SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38<sup>th</sup> Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm ET). The presentation will be webcast and may be accessed on the Company's website at <a href="http://www.neurocrine.com">http://www.neurocrine.com</a>.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

## **About Neurocrine Biosciences**

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD. The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

To view the original version on PR Newswire, visit: <u>http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-300471523.html</u>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, ir@neurocrine.com